Cited by 222Bacteriophages and microbial interactionsCRISPR and Genetic EngineeringVirus-based gene therapy research

Phages and their potential to modulate the microbiome and immunity

Open access
Federici, Sara, Nobs, Samuel P., Elinav, Eran·2021·Cellular & Molecular Immunology

Abstract

Bacteriophages (hence termed phages) are viruses that target bacteria and have long been considered as potential future treatments against antibiotic-resistant bacterial infection. However, the molecular nature of phage interactions with bacteria and the human host has remained elusive for decades, limiting their therapeutic application. While many phages and their functional repertoires remain unknown, the advent of next-generation sequencing has increasingly enabled researchers to decode new lytic and lysogenic mechanisms by which they attack and destroy bacteria. Furthermore, the last decade has witnessed a renewed interest in the utilization of phages as therapeutic vectors and as a means of targeting pathogenic or commensal bacteria or inducing immunomodulation. Importantly, the narrow host range, immense antibacterial repertoire, and ease of manipulating phages may potentially allow for their use as targeted modulators of pathogenic, commensal and pathobiont members of the microbiome, thereby impacting mammalian physiology and immunity along mucosal surfaces in health and in microbiome-associated diseases. In this review, we aim to highlight recent advances in phage biology and how a mechanistic understanding of phage-bacteria-host interactions may facilitate the development of novel phage-based therapeutics. We provide an overview of the challenges of the therapeutic use of phages and how these could be addressed for future use of phages as specific modulators of the human microbiome in a variety of infectious and noncommunicable human diseases.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41423-020-00532-4

Cites

240 of 240 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Phages can enhance antitumor immunity.

    “Phages can eliminate cancer-associated bacteria, remodel the tumor microenvironment, enhance antitumor immunity, and deliver targeted therapeutic payloads.”

    From Phage therapy in oncology: opportunities for cancer prevention and treatment (2026) · cites this paper as [21]

    The Introduction reports that phage-based antigen presentation can induce potent T-cell immunity, but does not identify this as antitumor immunity. It only speculates that phage immunomodulation may enable future cancer immunotherapies; it does not establish that phages enhance antitumor immunity. (LLM, conf=0.87)

    Experimental — accuracy not yet measured
  • Phage DNA and structural proteins engage pattern recognition receptors within innate immune pathways, thereby enhancing antitumor immune responses.

    “Additionally, phage DNA and structural proteins engage pattern recognition receptors within innate immune pathways, thereby enhancing antitumor immune responses [21,23–26]”

    From Phage therapy in oncology: opportunities for cancer prevention and treatment (2026) · cites this paper as [21]

    The Introduction (page unavailable) reports that phages can be recognized by innate Toll-like receptors, including TLR9, and that phage components can elicit immune responses. It does not establish that both phage DNA and structural proteins engage pattern-recognition receptors to enhance antitumor immunity; it only speculates that phage immunomodulation might enable future cancer immunotherapies. (LLM, conf=0.87)

    Experimental — accuracy not yet measured
  • Phages reshape tumor-associated bacterial communities.

    “Indirectly, phages reshape tumor-associated bacterial communities, depleting protumorigenic taxa and altering microbial metabolites that regulate inflammation, genotoxic stress, and therapeutic response [20–23]”

    From Phage therapy in oncology: opportunities for cancer prevention and treatment (2026) · cites this paper as [21]

    The Introduction reports that phages can affect the gut microbiome and its metabolites. The Concluding remarks suggest that phage-directed elimination of disease-associated bacteria may eventually benefit neoplastic disorders, but the paper does not report that phages reshape tumor-associated bacterial communities or deplete protumorigenic taxa. (LLM, conf=0.85)

    Experimental — accuracy not yet measured
  • Phages deplete protumorigenic taxa.

    “Indirectly, phages reshape tumor-associated bacterial communities, depleting protumorigenic taxa and altering microbial metabolites that regulate inflammation, genotoxic stress, and therapeutic response [20–23]”

    From Phage therapy in oncology: opportunities for cancer prevention and treatment (2026) · cites this paper as [21]

    The Concluding remarks (page unavailable) suggest that neoplastic disorders may benefit from phage-directed elimination of disease-associated bacteria. They present this as a potential therapy, not evidence that phages deplete protumorigenic taxa in tumor-associated communities. (LLM, conf=0.85)

    Experimental — accuracy not yet measured
  • Phages alter microbial metabolites that regulate inflammation, genotoxic stress, and therapeutic response.

    “Indirectly, phages reshape tumor-associated bacterial communities, depleting protumorigenic taxa and altering microbial metabolites that regulate inflammation, genotoxic stress, and therapeutic response [20–23]”

    From Phage therapy in oncology: opportunities for cancer prevention and treatment (2026) · cites this paper as [21]

    The Introduction (page unavailable) says phages strongly affect the gut metabolite repertoire through their effects on the microbiome. It does not establish that those metabolite changes regulate inflammation, genotoxic stress, or therapeutic response; its discussions of immunity and therapy do not link those outcomes to metabolites. (LLM, conf=0.87)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

2 of the 242 references couldn’t be matched to a known paper.

Cited by

Sorted by citations

Authors
Federici, S., Nobs, S. P., & Elinav, E.
Affiliations
  • Weizmann Institute of Science (IL)
  • German Cancer Research Center (DE)
Corresponding author
Elinav, Eran
Venue
Cellular & Molecular Immunology
Published
2020-09-08
Volume
18
Issue
4
Pages
889-904
ISSN
  • 1672-7681 (ISSN-L)
  • 2042-0226
OpenAlex
W3084223430
Cited by
222
References
242
Citations by year
2026: 49 · 2025: 55 · 2024: 42 · 2023: 38 · 2022: 26 · 2021: 12
FWCI
1.67
Type
journal article
Language
en
Open access
Locations
  • Cellular and Molecular Immunology (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
Funders
Howard Hughes Medical Institute
Topics
  • Physical Sciences › Environmental Science › Ecology › Bacteriophages and microbial interactions
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › CRISPR and Genetic Engineering
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
Keywords
bacteriophages, phage therapy, human microbiome, phage-bacteria interactions, antibiotic resistance, immunomodulation, mucosal immunity, commensal bacteria, pathobionts, phage vectors
MeSH terms
Phage Therapy, Animals, Bacteria, Bacterial Infections, Bacteriophages, Humans, Drug Resistance, Multiple, Bacterial

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review